Brainsway Ltd
BRSYF
Get informed when a big investor buys or sells
+ FollowMarket Cap$675.68M
Close$
$1.93
85.7% downside
Current Fair Value
85.7% downsideOvervalued by 85.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $675.68 Million |
|---|---|
| Enterprise Value | $635.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0.15 |
| Outstanding Shares | 38,166,667 |
Return
| Return on Equity | 12.46% |
|---|---|
| Return on Assets | 8.07% |
| Return on Invested Capital | 5.95% |
Valuation & Multiples
| P/E Ratio | 64.58 |
|---|---|
| PEG | 60.43 |
| Price to Sales | 13.55 |
| Price to Book Ratio | 13.55 |
| Enterprise Value to Revenue | 10.5 |
| Enterprise Value to EBIT | 114.32 |
| Enterprise Value to Net Income | 67 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$15.92 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$16.31 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Brainsway Ltd.
CEO: Christopher von Jako Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...